The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico. Non-US residents click here.

5-Year Data See the results of the longest reported controlled clinical study of male pattern hair loss. View study results.

AAD Meetings Annual Meetings 2006 Annual Meeting January 8–14 Los Cabos, Mexico Summer Meetings 2005 ACADEMY '05 July 20–24 Hyatt Regency Chicago, Ill Go to www.aad.org for more information on AAD meetings. Important Information About PROPECIA® (finasteride)   PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established.   PROPECIA is not indicated in women or children.   Patient Brochure Order Samples Links

	PROPECIA is a registered trademark of Merck & Co., Inc. 20550391(1)-03/08-PRP